Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL6001231 | 0.88 | CYP17A1 (0.41) | CYP17A1CYP19A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL377276 | 0.85 | CYP17A1 (0.63) | CYP17A1CYP19A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13126150 | 0.85 | CYP17A1 (0.42) | CYP17A1CYP19A1SLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL5999961 | 0.85 | CYP17A1 (0.54) | CYP17A1PDE4ASLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL5999950 | 0.82 | CYP17A1 (0.57) | CYP17A1CYP19A1SLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL6000329 | 0.82 | CYP17A1 (0.58) | CYP17A1CYP19A1PDE4ASLC6A2SLC6A4 | |
| Ammonia Solution, Strong SCHEMBL5999712 | 0.82 | SLC6A3 (0.59) | CYP17A1SLC6A2SLC6A4SLC6A3S1PR1 | |
| Ammonia Solution, Strong SCHEMBL6000241 | 0.81 | CYP17A1 (0.51) | CYP17A1CYP19A1PDE4ASLC6A2SLC6A4 | |
| Ammonia Solution, Strong SCHEMBL5999435 | 0.81 | POLB (0.50) | CYP19A1SLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL5999692 | 0.81 | CYP19A1 (0.59) | CYP17A1CYP19A1PDE4ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCE, INC. (US) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | CYP17A1 4384/4885CYP19A1 4624/4885PDE4A 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.